Cerep and Roche Extend their Collaboration on BioPrint®
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Cerep announces the extension of the strategic collaboration concluded in 2009 with Roche on BioPrint®, the Company’s homogenous pharmacology and ADME 1 database, which provides a resource for supporting decision making in drug discovery.
At the end of the first collaboration year, Roche exercised the option to pursue the evaluation license agreement for an additional year to explore other fields of interest. Discussions regarding the content of the scientific program for the second collaboration year are ongoing.
Roche will be granted a web access to the BioPrint® database and related pharmaco-informatics tools for a limited number of users. Upon termination of the evaluation license, Roche will have the option to subscribe a perpetual license at a predetermined price. Cerep will receive an annual license fee and additional payments for the generation of new BioPrint® data.
“We are very happy to extend this collaboration with Roche on BioPrint®. The first collaboration year raised a lot of enthusiasm on both sides and led to interesting scientific publications based on new hypotheses explored through this partnership. The expansion of the collaboration for an additional year will be a great opportunity to further develop these original ideas”, commented Thierry Jean, President & CEO of Cerep.
At the end of the first collaboration year, Roche exercised the option to pursue the evaluation license agreement for an additional year to explore other fields of interest. Discussions regarding the content of the scientific program for the second collaboration year are ongoing.
Roche will be granted a web access to the BioPrint® database and related pharmaco-informatics tools for a limited number of users. Upon termination of the evaluation license, Roche will have the option to subscribe a perpetual license at a predetermined price. Cerep will receive an annual license fee and additional payments for the generation of new BioPrint® data.
“We are very happy to extend this collaboration with Roche on BioPrint®. The first collaboration year raised a lot of enthusiasm on both sides and led to interesting scientific publications based on new hypotheses explored through this partnership. The expansion of the collaboration for an additional year will be a great opportunity to further develop these original ideas”, commented Thierry Jean, President & CEO of Cerep.
